Group 1 - The core business of the company is the development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2] - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment, centered around precise interventional navigation [2] - The company has several key products, including the Columbus 3D cardiac electrophysiology mapping system and various disposable electrophysiological catheters [2] Group 2 - As of March 31, 2025, the company had 7,764 shareholders, a decrease of 209 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's latest quarterly report for Q1 2025 shows a revenue of 104 million yuan, a year-on-year increase of 16.77%, and a net profit of 17.87 million yuan, a year-on-year increase of 328.63%, with a gross margin of 60.56% [3] - The company's rolling PE ratio is 163.35, significantly higher than the industry average of 55.76 and the industry median of 39.14, ranking 111th in the medical device sector [1][3]